DV
Dividend Vision

XFOR — X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc (XFOR)

Total return is -99.8% over the past 8.7 years, 343.5 points behind SPY at 243.7%. Its deepest 1-year drawdown was 37.6%.

X4 Pharmaceuticals is a biopharmaceutical company focused on researching, developing, and commercializing novel therapeutics for rare immune system diseases. The company's lead candidate, XOLREMDI, is an oral CXCR4 antagonist currently in phase 3 clinical trials for treating warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, with licensing agreements in place for commercialization in China, Europe, Australia, and New Zealand. The company does not currently distribute dividends, making it primarily suited for growth-oriented investors rather than income-focused ones.

XFOR key facts

Asset type
Stock
Asset class
Equity
Inception date
11/16/2017
Last close
$4.22
Market cap
$347,096,480
Average volume
840900.0
Payment date
03/14/2019
Beta
0.354
Payout ratio
0.0
P/E ratio
3.0
Forward P/E
0.0
EPS
$-1.99